MARKET

AGEN

AGEN

Agenus
NASDAQ
3.470
+0.030
+0.87%
Pre Market: 3.470 0 0.00% 04:00 05/14 EDT
OPEN
3.410
PREV CLOSE
3.440
HIGH
3.580
LOW
3.390
VOLUME
979
TURNOVER
0
52 WEEK HIGH
7.34
52 WEEK LOW
2.710
MARKET CAP
144.50M
P/E (TTM)
2.089
1D
5D
1M
3M
1Y
5Y
1D
Agenus Buy Rating Reaffirmed as Late-Stage Strategy Advances; $23 Price Target Maintained
TipRanks · 2d ago
Midday Fly By: Dream Finders offers to buy Beazer, Fox reports Q3 beat
TipRanks · 2d ago
Agenus: Q1 Earnings Snapshot
Barchart · 2d ago
Agenus reports Q1 revenue $33.7M vs. $24.1M last year
TipRanks · 2d ago
Agenus provides 2026 strategic priorities
TipRanks · 2d ago
Agenus announces conclusion of SEC investigation with no enforcement action
TipRanks · 2d ago
Agenus reports Q1 results
Seeking Alpha · 3d ago
Immuno-oncology developer Agenus' Q1 revenue rises, posts profit
Reuters · 3d ago
More
About AGEN
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.

Webull offers Agenus Inc stock information, including NASDAQ: AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.